Surrozen to Present at Canaccord Genuity’s 41st Annual Growth Conference
August 05, 2021 08:00 ET
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc. (Nasdaq: SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt...
Surrozen Presents New Data Demonstrating Superior Activity of SZN-1326 in Preclinical Inflammatory Bowel Disease Models at 16th Congress of the European Crohn’s and Colitis Organisation (ECCO)
July 09, 2021 08:00 ET
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., July 09, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, announced...
Surrozen Presents Data at 2021 International Liver Conference for Wnt-Modulating Antibody SZN-043
June 25, 2021 08:00 ET
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., June 25, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, announced...
Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Biology Conference: Fundamental Mechanisms and Translational Applications
June 17, 2021 08:00 ET
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., June 17, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, announced...
Surrozen Publishes Article in Nature Communications Demonstrating Selective Wnt Mimetics Stimulate Bone Mass Accrual in Disease Models of Osteoporosis, Aging and Long-Bone Fracture
June 01, 2021 08:00 ET
|
Surrozen, Inc.
Results Demonstrate Rapid and Robust Bone-building Effects from Selective Wnt Agonists in Proof of Concept, Preclinical Studies of Wnt Mimetics for the Treatment of Diseases of Low Bone Mineral...
Surrozen Presents Data from Lead Wnt-Modulating Antibody Programs, SZN-1326 and SZN-043, in Six Oral and Poster Presentations at 2021 Digestive Disease Week Conference
May 24, 2021 08:00 ET
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., May 24, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, announced...
Surrozen Strengthens Board of Directors with Appointments of Mace Rothenberg, M.D., and Christopher Chai
May 06, 2021 08:00 ET
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today...
Surrozen Expands Board of Directors with Appointment of Mary Haak-Frendscho, Ph.D.
March 11, 2021 14:37 ET
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today...
Surrozen Expands Board of Directors with Appointment of Shao-Lee Lin, M.D., Ph.D.
February 02, 2021 18:31 ET
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today...
Surrozen to Present at the Stifel 2020 Virtual Healthcare Conference
November 12, 2020 07:00 ET
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced that Craig Parker,...